Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608466 | 0.78 | APP (0.52) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL12573274 | 0.78 | APP (0.57) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL1249856 | 0.78 | MEN1 (0.45) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL1607485 | 0.73 | APP (0.45) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL1251703 | 0.73 | APP (0.52) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL13863154 | 0.71 | APP (0.56) | APPNPC1MAPTRAB9A | |
| SCHEMBL1250859 | 0.71 | RAB9A (0.79) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL13863150 | 0.71 | APP (0.56) | APPNPC1MAPTRAB9A | |
| SCHEMBL1250279 | 0.71 | RAB9A (0.79) | APPNPC1MAPTMAPK1RAB9A | |
| SCHEMBL1249681 | 0.70 | TNIK (0.55) | APPNPC1MAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | claimed |
| EP-2285789-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | Merck Sharp & Dohme Corp. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | claimed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | APP, PSEN1, BACE1 | APP 1/4885NPC1 129/4885MAPT 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.